The Company reported a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, ...

As the rollout of its recently launched pulmonary arterial hypertension (PAH) drug Winrevair ramps up, Merck is continuing ...

"The financing we concluded in October was a transformational moment for Inhibikase, and positioned us to advance IkT-001Pro ...

American Lung Association launches campaign to improve lives of people living with pulmonary arterial hypertension </p ...

The oxygen gets taken up by the body and the blood cycles back to the heart. When all things are working well, the blood ...

Serge Belanger’s rating is based on a clear path toward FDA approval and the subsequent launch of Yutrepia, a drug developed by Liquidia Technologies for treating pulmonary arterial hypertension (PAH) ...

Received tentative approval from the FDA for YUTREPIA™ (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung ...

The study demonstrates that activating the vitamin D receptor (VDR) with calcitriol suppresses cell proliferation in ...

Medical Dialogues presents a rare disease series, delving into the realm of uncommon medical conditions. Rare diseases are ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia – – Topline data from 1-year open-label extension (OLE) trial now expected in December 2024 – ...